Adhesion and Safety of Rotigexole Compared to Neupro®

Summary

A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the innovator product, Neupro® 8 mg/ 24 hours transdermal patch, manufactured by UCB Pharma S.A., Belgium, after 24 hours of application

Timeline

Start

2025-09-01

Primary completion

2025-10-15

Completion

2025-10-30

Drugs

Indications